Table 3.

Overview of complement therapeutics for clinical trials.

Target	Indication	Primary endpoint	Participants	References
C1 esterase	Trauma or sepsis	Measurement of C1-inhibitor levels, complement concentration and activity, and cytokines; Analysis of neutrophil phenotype and hemodynamic response	Terminated: Study showed limited feasibility	NCT01275976
C1 esterase	Endotoxemia Inflammation MODS	Measurement of C1-inhibitor levels, complement concentration and activity, Cytokines, and markers of inflammation; Analysis of neutrophil phenotype, and hemodynamic response; Assessment of renal injury	20	NCT00785018
C5a	Severe sepsis Septic shock	Evaluation of pharmacodynamic (PD) effects of the C5a antibody	72	NCT02246595